Biosimilar Red Tape Elimination Act

HR 5526, the Biosimilar Red Tape Elimination Act, streamlines the U.S. Food and Drug Administration’s (FDA) process for approving biosimilar drugs that can be used interchangeably with brand-name biologic medications. It establishes a 60-day transition period after enactment to clarify when biosimilars are deemed "interchangeable" with reference drugs, preserving existing exclusivity periods for products licensed before the law’s passage. This affects pharmaceutical manufacturers developing biosimilars, the FDA (which must update its guidance within 18 months), and healthcare systems seeking lower-cost treatment options. The bill removes redundant language from existing laws and ensures the FDA’s approval standards for biosimilars remain unchanged, focusing on regulatory clarity rather than altering drug safety or efficacy requirements.